相关实验视频

Updated: Sep 13, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

在POSEIDON组1和2中重复试管婴儿周期的淋巴激素剂量选择

Hao Wei¹, JinLiang Duan¹, SiShi Wang¹

¹Reproductive Medical Center, The 924th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army, Guilin, China.

Frontiers in endocrinology

|August 1, 2025

概括

在第二次体外受精 (IVF) 周期中增加淋巴激素 (Gn) 剂量并没有改善POSEIDON组1和2的活产率. 这一策略增加了成本,但在累积活产率 (CLBR) 上没有显著的好处.

科学领域:

生殖医学生殖医学
不孕症治疗不孕症治疗
辅助生殖技术辅助生殖技术

背景情况:

根据POSEIDON分类,根据年龄和卵巢储备进行体外受精 (IVF) 的患者分层.
波西顿1组和2组代表了卵巢反应 (POR) 较差或预期的POR患者.
优化卵巢刺激方案对于改善这些患者群体的试管婴儿结果至关重要.

研究的目的:

调查第二次试管婴儿周期中增加淋巴激素 (Gn) 剂量是否会改善POSEIDON组1和2患者的累积活产率 (CLBR).
评估Gn剂量升级对卵细胞产量,受精和胚胎细胞形成率的影响.
为了确定在随后的试管婴儿周期中增加Gn剂量的成本效益.

主要方法:

在POSEIDON组1和2的343名患者的回顾性研究中,他们经历了两个连续的试管婴儿周期,并使用了对抗剂协议.
患者被分为"添加剂"组 (在第二个周期中增加了Gn剂量) 和"控制"组 (维持或减少了Gn剂量).
倾向性得分匹配 (1:2比) 用于平衡基线特征;CLBR是主要结果.

主要成果:

添加剂组在第二个周期中获得了更高的初始和总Gn剂量,但检索的卵细胞,MII卵细胞和2PN受精率的差异在统计学上并不显著.
发芽细胞形成率在各组之间是相似的 (44.9%与44.2%,P=0.937).
对照组的CLBR略高一些,但在统计学上没有显著性 (31.5%对28.9%,P=0.8).

结论:

在第二次试管婴儿周期中增加 Gn 剂量,对于 POSEIDON 组 1 和组 2 使用对抗剂协议,不会增强 CLBR.
升级Gn剂量导致治疗成本增加,而没有明显改善活产率.
对于这些患者群体,不建议在随后的循环中增加Gn的常规剂量.

关键词:

波赛顿 (POSEIDON) 是一个反对者的协议协议.累积的活产率是指累积的活产率.淋巴激素的剂量淋巴激素的剂量在体外受精体外受精.

更多相关视频

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

相关概念视频

In Vitro Fertilization

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

Meiosis II

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...